Amylyx Pharmaceuticals (AMLX) Interest & Investment Income (2021 - 2026)

Amylyx Pharmaceuticals has reported Interest & Investment Income for 6 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 18.52% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $10.0 million, a 4.15% increase from a year earlier, with the FY2025 full-year figure at $9.3 million, down 32.64% from the prior year.
• Interest & Investment Income was $2.3 million for Q2 2026 at Amylyx Pharmaceuticals, down from $2.6 million in the prior quarter.
• The five-year high for Interest & Investment Income was $4.4 million in Q4 2023, with the low at $131000.0 in Q1 2022.
• Average Interest & Investment Income over 5 years is $2.7 million, with a median of $2.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income surged 40100.0% in 2022, then tumbled 51.83% in 2025.
• Over 5 years, Interest & Investment Income stood at $3.2 million in 2022, then jumped by 38.45% to $4.4 million in 2023, then tumbled by 47.01% to $2.3 million in 2024, then surged by 42.06% to $3.3 million in 2025, then decreased by 29.39% to $2.3 million in 2026.
• The last three Interest & Investment Income figures came in at $2.3 million (Q2 2026), $2.6 million (Q1 2026), and $3.3 million (Q4 2025), per Business Quant data.